Skip to main content
. 2023 Jun 8;93:104590. doi: 10.1016/j.ebiom.2023.104590

Fig. 6.

Fig. 6

Predicted prevention efficacy of fixed dose versus body weight-dose of the triple bnAb regimen PGT121LS + PGDM1400LS + VRC07-523LS and of VRC01 at steady state against (a) HVTN703/HPTN 081 placebo viruses (n = 47) and (b) HVTN704/HPTN 085 placebo viruses (n = 70) circulating in each AMP trial. All predictions were made under the scenario that PGT121LS and PGDM1400LS have 5-fold higher half-lives than PGT121 and PGDM1400, based on modelling of the observed serum concentration data of PGT12127 and PGDM1400.19 Predicted prevention efficacy at steady state was based on prevention efficacy vs. PT80 curve in AMP12 and Pegu et al.,5 solid line: median. Shaded area: 95% prediction interval.